Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.31 |
| ▸ | PRCP | P42785 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10219095 | 1.00 | PLG (0.33) | PLGLTA4HPARP1CXCR4PRCP | |
| SCHEMBL4725538 | 1.00 | PLG (0.33) | PLGLTA4HPARP1CXCR4PRCP | |
| Hydrochloric Acid SCHEMBL3859764 | 0.98 | PLG (0.33) | PLGLTA4HPARP1CXCR4 | |
| SCHEMBL8203610 | 0.98 | CXCR4 (0.33) | PLGLTA4HPARP1CXCR4 | |
| SCHEMBL9831374 | 0.87 | CXCR4 (0.39) | PLGCXCR4 | |
| SCHEMBL26819750 | 0.83 | CXCR4 (0.32) | CXCR4 | |
| SCHEMBL27755487 | 0.83 | PLG (0.32) | PLGLTA4H | |
| SCHEMBL14156651 | 0.83 | LTA4H (0.31) | LTA4HPARP1 | |
| SCHEMBL4835743 | 0.83 | LTA4H (0.31) | LTA4HPARP1 | |
| SCHEMBL4835738 | 0.83 | LTA4H (0.31) | LTA4HPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140273458-A1 | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| EP-2779217-A2 | Chemical mechanical planarization for tungsten-containing substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-17 | — | — | EP | claimed |
| US-4705788-A | Novel antibacterial 7-amino-1(substituted cyclopropyl)-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids | BAYER AKTIENGESELLSCHAFT (DE) | 1987-11-10 | — | — | US | claimed |
| CN-119410046-A | Waterproof flame-retardant polyethylene composite material and preparation method and application thereof | 重庆科聚孚新材料有限责任公司 | 2025-02-11 | — | — | CN | disclosed |
| EP-3784669-B1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMA (US) | 2023-10-25 | — | — | EP | disclosed |
| US-11566003-B2 | Isoquinolines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-11414764-B2 | Method of inhibiting metal corrosion with a piperazine-based polyurea | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2022-08-16 | — | — | US | disclosed |
| US-11332470-B2 | CXCR4 inhibitors and uses thereof | X4 PHARMACEUTICALS, INC. (US) | 2022-05-17 | — | — | US | disclosed |
| US-11306088-B2 | CXCR4 inhibitors and uses thereof | X4 PHARMACEUTICALS, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| US-20210363139-A1 | CXCR4 INHIBITORS AND USES THEREOF | X4 PHARMACEUTICALS, INC. | 2021-11-25 | — | — | US | disclosed |
| US-20210300912-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | Ikena Oncology, Inc. | 2021-09-30 | — | — | US | disclosed |
| US-4556658-A | 7-Amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acids and antibacterial agents containing these compounds | BAYER AKTIENGESELLSCHAFT (DE) | 1985-12-03 | — | — | US | disclosed |
| US-4544658-A | FEED ADDITIVES | BAYER AKTIENGESELLSCHAFT (DE) | 1985-10-01 | — | — | US | disclosed |
| US-4525589-A | Isoquinolinesulfonyl derivatives | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1985-06-25 | — | — | US | disclosed |
| EP-0126355-A1 | 7-Amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinoline-carboxylic acid, processes for their preparation and antibacterial agents containing them | BAYER AG (DE) | 1984-11-28 | — | — | EP | disclosed |
| EP-0061673-B1 | ISOQUINOLINESULFONYL DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1984-10-24 | — | — | EP | disclosed |
| EP-0113093-A1 | 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(alkyl-1-piperazinyl)-3-quinoline-carboxylic acids, process for their preparation and antibacterial agents containing them | BAYER AG (DE) | 1984-07-11 | — | — | EP | disclosed |
| US-4456757-A | MUSCLE RELAXANTS, VASODILATORS, HYPOTENSIVE AGENTS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1984-06-26 | — | — | US | disclosed |
| EP-0061673-A1 | Isoquinolinesulfonyl derivatives and process for the preparation thereof | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1982-10-06 | — | — | EP | disclosed |
| US-4321061-A | Motor fuel | PHILLIPS PETROLEUM COMPANY (US) | 1982-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300912-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | AHR, ARNT, HCAR1 | PLG 4177/4885LTA4H 311/4885PARP1 3200/4885 |
| US-20210363139-A1 | CXCR4 INHIBITORS AND USES THEREOF | CXCR4, CXCL12, CXCR3 | PLG 1404/4885LTA4H 484/4885PARP1 1166/4885 |
| US-11566003-B2 | Isoquinolines as inhibitors of HPK1 | HIPK1, HIPK2, IP6K1 | PLG 4337/4885LTA4H 2096/4885PARP1 1957/4885 |
| US-11306088-B2 | CXCR4 inhibitors and uses thereof | CXCR4, CXCL12, CXCR3 | PLG 1404/4885LTA4H 484/4885PARP1 1166/4885 |
| US-11332470-B2 | CXCR4 inhibitors and uses thereof | CXCR4, CXCL12, CXCR3 | PLG 1404/4885LTA4H 484/4885PARP1 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.